Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial.

Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF.

Crit Care Resusc. 2017 Mar;19(1):43-49.

PMID:
28215131
2.

Ethyl pyruvate modulates delayed paralysis following thoracic aortic ischemia reperfusion in mice.

Nguyen BN, Albadawi H, Oklu R, Crawford RS, Fink MP, Cambria RP, Watkins MT.

J Vasc Surg. 2016 Nov;64(5):1433-1443. doi: 10.1016/j.jvs.2015.06.214.

3.

Integrated Critical Care Organizations: A Personal View.

Fink MP.

Crit Care Med. 2015 Oct;43(10):2047-8. doi: 10.1097/CCM.0000000000001286. No abstract available.

PMID:
26376246
4.

Analyzing the value of monitoring duodenal mucosal perfusion using photoplethysmography.

Fink MP.

Crit Care. 2014 Oct 13;18(5):561. doi: 10.1186/s13054-014-0561-6.

5.

Cytopathic hypoxia and sepsis: is mitochondrial dysfunction pathophysiologically important or just an epiphenomenon.

Fink MP.

Pediatr Crit Care Med. 2015 Jan;16(1):89-91. doi: 10.1097/PCC.0000000000000299. No abstract available.

PMID:
25560289
6.

Strategies to improve drug development for sepsis.

Fink MP, Warren HS.

Nat Rev Drug Discov. 2014 Oct;13(10):741-58. doi: 10.1038/nrd4368. Epub 2014 Sep 5. Review.

PMID:
25190187
7.

HMGB1 as a drug target in staphylococcal pneumonia.

Fink MP.

Crit Care. 2014 Mar 31;18(2):131. doi: 10.1186/cc13810.

8.

Nitric oxide synthase and vascular dysfunction in sepsis: should we target nitric oxide synthase 1, nitric oxide synthase 2, both, or neither?

Fink MP.

Crit Care Med. 2014 Jun;42(6):1572-5. doi: 10.1097/CCM.0000000000000355. No abstract available.

PMID:
24836806
9.

p-Hydroxyphenylpyruvate, an intermediate of the Phe/Tyr catabolism, improves mitochondrial oxidative metabolism under stressing conditions and prolongs survival in rats subjected to profound hemorrhagic shock.

Cotoia A, Scrima R, Gefter JV, Piccoli C, Cinnella G, Dambrosio M, Fink MP, Capitanio N.

PLoS One. 2014 Mar 5;9(3):e90917. doi: 10.1371/journal.pone.0090917. eCollection 2014.

10.

Acute pancreatitis: a lame duct problem?*.

Fink MP.

Crit Care Med. 2014 Mar;42(3):757-8. doi: 10.1097/CCM.0000000000000154. No abstract available.

PMID:
24534975
11.

Successful use of extracorporeal membrane oxygenation in an adult patient with toxic shock-induced heart failure.

Gabel E, Gudzenko V, Cruz D, Ardehali A, Fink MP.

J Intensive Care Med. 2015 Feb;30(2):115-8. doi: 10.1177/0885066613517069. Epub 2013 Dec 25.

PMID:
24371250
12.

Animal models of sepsis.

Fink MP.

Virulence. 2014 Jan 1;5(1):143-53. doi: 10.4161/viru.26083. Epub 2013 Aug 19. Review.

13.

Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: relatively safe and possibly effective.

Fink MP.

Crit Care Med. 2013 Sep;41(9):2221-3. doi: 10.1097/CCM.0b013e3182964037. No abstract available.

PMID:
23979366
14.

Pathophysiology of perioperative anaemia.

Singh S, Gudzenko V, Fink MP.

Best Pract Res Clin Anaesthesiol. 2012 Dec;26(4):431-9. doi: 10.1016/j.bpa.2012.11.002. Review.

PMID:
23351230
15.

Identification of a novel pathway of transforming growth factor-β1 regulation by extracellular NAD+ in mouse macrophages: in vitro and in silico studies.

Zamora R, Azhar N, Namas R, Metukuri MR, Clermont T, Gladstone C, Namas RA, Hermus L, Megas C, Constantine G, Billiar TR, Fink MP, Vodovotz Y.

J Biol Chem. 2012 Sep 7;287(37):31003-14. doi: 10.1074/jbc.M112.344309. Epub 2012 Jul 24.

16.

Pharmacological effects of inhaled methane: plausible or not?

Fink MP.

Crit Care Med. 2012 Apr;40(4):1379-80. doi: 10.1097/CCM.0b013e31824a5160. No abstract available.

PMID:
22425854
17.

Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsis.

Fink MP.

Crit Care Med. 2012 Feb;40(2):655-6. doi: 10.1097/CCM.0b013e31823b97d7. No abstract available.

PMID:
22249033
18.

A comparison of critical care research funding and the financial burden of critical illness in the United States.

Coopersmith CM, Wunsch H, Fink MP, Linde-Zwirble WT, Olsen KM, Sommers MS, Anand KJ, Tchorz KM, Angus DC, Deutschman CS.

Crit Care Med. 2012 Apr;40(4):1072-9. doi: 10.1097/CCM.0b013e31823c8d03.

PMID:
22202712
19.

L-arginine is a radioprotector for hematopoietic progenitor cells.

Pearce LL, Zheng X, Martinez-Bosch S, Kerr PP, Khlangwiset P, Epperly MW, Fink MP, Greenberger JS, Peterson J.

Radiat Res. 2012 Jun;177(6):792-803. Epub 2011 Dec 16.

20.

Transcriptomic response of murine liver to severe injury and hemorrhagic shock: a dual-platform microarray analysis.

Edmonds RD, Vodovotz Y, Lagoa C, Dutta-Moscato J, Yang Y, Fink MP, Levy RM, Prince JM, Kaczorowski DJ, Tseng GC, Billiar TR.

Physiol Genomics. 2011 Oct 20;43(20):1170-83. doi: 10.1152/physiolgenomics.00020.2011. Epub 2011 Aug 9.

21.

Organized staffing directed by intensivists improves outcomes for critically ill patients.

Fink MP.

Am J Transplant. 2011 Apr;11(4):645-6. doi: 10.1111/j.1600-6143.2011.03472.x. No abstract available.

22.

Ethyl pyruvate therapy attenuates experimental severe arthritis caused by type II collagen (CII) in the mouse (CIA).

Di Paola R, Mazzon E, Galuppo M, Esposito E, Bramanti P, Fink MP, Cuzzocrea S.

Int J Immunopathol Pharmacol. 2010 Oct-Dec;23(4):1087-98.

PMID:
21244758
23.

Postischemic treatment with ethyl pyruvate prevents adenosine triphosphate depletion, ameliorates inflammation, and decreases thrombosis in a murine model of hind-limb ischemia and reperfusion.

Crawford RS, Albadawi H, Atkins MD, Jones JJ, Conrad MF, Austen WG Jr, Fink MP, Watkins MT.

J Trauma. 2011 Jan;70(1):103-10; discussion 110. doi: 10.1097/TA.0b013e3182031ccb.

24.

Preconditioning with high mobility group box 1 (HMGB1) induces lipoteichoic acid (LTA) tolerance.

Robert SM, Sjodin H, Fink MP, Aneja RK.

J Immunother. 2010 Sep;33(7):663-71. doi: 10.1097/CJI.0b013e3181dcd111.

25.

The therapeutic potential of pyruvate.

Fink MP.

J Surg Res. 2010 Dec;164(2):218-20. doi: 10.1016/j.jss.2010.01.046. Epub 2010 Feb 21. No abstract available.

PMID:
20451918
26.

The biochemical basis for the anti-inflammatory and cytoprotective actions of ethyl pyruvate and related compounds.

Kao KK, Fink MP.

Biochem Pharmacol. 2010 Jul 15;80(2):151-9. doi: 10.1016/j.bcp.2010.03.007. Epub 2010 Mar 15. Review.

PMID:
20230800
27.

Editorial: Lepromatous leprosy, lipids, and lessons in immunology: what we can learn by using modern methods to study an ancient disease.

Fink MP.

J Leukoc Biol. 2010 Mar;87(3):361-3. doi: 10.1189/jlb.1009685. No abstract available.

PMID:
20194162
28.

Effects of ethyl pyruvate and other α-keto carboxylic acid derivatives in a rat model of multivisceral ischemia and reperfusion.

Cruz RJ Jr, Harada T, Sasatomi E, Fink MP.

J Surg Res. 2011 Jan;165(1):151-7. doi: 10.1016/j.jss.2009.07.008. Epub 2009 Aug 7.

PMID:
19959189
29.

Editorial: Hemopexin: newest member of the anti-inflammatory mediator club.

Fink MP.

J Leukoc Biol. 2009 Aug;86(2):203-4. doi: 10.1189/jlb.0309137. No abstract available.

PMID:
19643739
30.

Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1.

Fink MP.

Crit Care Med. 2009 Aug;37(8):2483-5. doi: 10.1097/CCM.0b013e3181abf5f4. No abstract available.

PMID:
19609124
31.

Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia.

Yang R, Miki K, Oksala N, Nakao A, Lindgren L, Killeen ME, Mennander A, Fink MP, Tenhunen J.

Am J Physiol Regul Integr Comp Physiol. 2009 Aug;297(2):R362-9. doi: 10.1152/ajpregu.00184.2009. Epub 2009 Jun 3.

32.

Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.

Davé SH, Tilstra JS, Matsuoka K, Li F, DeMarco RA, Beer-Stolz D, Sepulveda AR, Fink MP, Lotze MT, Plevy SE.

J Leukoc Biol. 2009 Sep;86(3):633-43. doi: 10.1189/jlb.1008662. Epub 2009 May 19.

33.

Peroxisome proliferator activator receptor gamma (PPARgamma) agonists as therapeutic adjuncts in critical illness: efficacy might be suboptimal in elderly patients.

Fink MP.

Crit Care Med. 2009 Jun;37(6):2123-5. doi: 10.1097/CCM.0b013e3181a5bfe5. No abstract available.

PMID:
19448468
34.

Comparison of distinct protein isoforms of the receptor for advanced glycation end-products expressed in murine tissues and cell lines.

Gefter JV, Shaufl AL, Fink MP, Delude RL.

Cell Tissue Res. 2009 Jul;337(1):79-89. doi: 10.1007/s00441-009-0791-0. Epub 2009 May 5.

PMID:
19415334
35.

Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicity.

Yang R, Miki K, He X, Killeen ME, Fink MP.

Crit Care. 2009;13(2):R55. doi: 10.1186/cc7782. Epub 2009 Apr 9.

36.

Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in mice.

Di Paola R, Mazzon E, Genovese T, Crisafulli C, Bramanti P, Caminiti R, Esposito E, Fink MP, Cuzzocrea S.

Crit Care Med. 2009 Jan;37(1):270-82. doi: 10.1097/CCM.0b013e318192fa63.

PMID:
19050619
37.

Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis.

Yang R, Shaufl AL, Killeen ME, Fink MP.

J Surg Res. 2009 May 15;153(2):302-9. doi: 10.1016/j.jss.2008.04.004. Epub 2008 May 2.

PMID:
19027919
38.

Beneficial effects of ethyl pyruvate in a mouse model of spinal cord injury.

Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Caminiti R, Bramanti P, Fink MP, Cuzzocrea S.

Shock. 2009 Aug;32(2):217-27. doi: 10.1097/SHK.0b013e31818d4073.

PMID:
18948848
39.

A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass.

Bennett-Guerrero E, Swaminathan M, Grigore AM, Roach GW, Aberle LG, Johnston JM, Fink MP.

J Cardiothorac Vasc Anesth. 2009 Jun;23(3):324-9. doi: 10.1053/j.jvca.2008.08.005. Epub 2008 Oct 4.

PMID:
18835526
40.

Animal models of sepsis and its complications.

Fink MP.

Kidney Int. 2008 Oct;74(8):991-3. doi: 10.1038/ki.2008.442. Review.

41.

Preconditioning with high mobility group box 1 (HMGB1) induces lipopolysaccharide (LPS) tolerance.

Aneja RK, Tsung A, Sjodin H, Gefter JV, Delude RL, Billiar TR, Fink MP.

J Leukoc Biol. 2008 Nov;84(5):1326-34. doi: 10.1189/jlb.0108030. Epub 2008 Aug 7.

42.

Drag-reducing hyaluronic acid increases survival in profoundly hemorrhaged rats.

Cotoia A, Kameneva MV, Marascalco PJ, Fink MP, Delude RL.

Shock. 2009 Mar;31(3):258-61. doi: 10.1097/SHK.0b013e31817fc434.

PMID:
18650778
43.

Ethyl pyruvate.

Fink MP.

Curr Opin Anaesthesiol. 2008 Apr;21(2):160-7. doi: 10.1097/ACO.0b013e3282f63c2e. Review.

PMID:
18443482
44.

Neuropeptide modulators of high mobility group box 1 secretion as potential therapeutic agents for severe sepsis.

Fink MP.

Am J Pathol. 2008 May;172(5):1171-3. doi: 10.2353/ajpath.2008.080161. Epub 2008 Apr 10. No abstract available.

45.

Targeting mitochondria.

Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE.

Acc Chem Res. 2008 Jan;41(1):87-97. doi: 10.1021/ar700135m. Review. Erratum in: Acc Chem Res. 2012 Dec 18;45(12):2222.

PMID:
18193822
46.

Ethyl pyruvate, a potentially effective mitigator of damage after total-body irradiation.

Epperly M, Jin S, Nie S, Cao S, Zhang X, Franicola D, Wang H, Fink MP, Greenberger JS.

Radiat Res. 2007 Nov;168(5):552-9.

PMID:
17973549
47.
48.

Hemigramicidin-TEMPO conjugates: novel mitochondria-targeted antioxidants.

Fink MP, Macias CA, Xiao J, Tyurina YY, Delude RL, Greenberger JS, Kagan VE, Wipf P.

Crit Care Med. 2007 Sep;35(9 Suppl):S461-7. Review.

PMID:
17713394
49.

Administration of exogenous cytochrome c as a novel approach for the treatment of cytopathic hypoxia.

Fink MP.

Crit Care Med. 2007 Sep;35(9):2224-5. No abstract available.

PMID:
17713377
50.

Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.

Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, Fine J, Krichevsky A, Delude RL, Angus DC; GenIMS Investigators.

Arch Intern Med. 2007 Aug 13-27;167(15):1655-63.

Supplemental Content

Support Center